Method for constructing functional exosome

The construction of functional exosomes through Gateway cloning technology solves the problem of low efficiency in the existing technology, realizes high-throughput rapid cloning and screening, and improves the efficiency and accuracy of functional research of exosomes. In a variety of functional applications.

CN119061035APending Publication Date: 2024-12-03GUANGZHOU FULENGEN
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310647684.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and high-throughput operation to build functional exosomes, and the lack of efficient labeling and screening methods affects the efficiency and accuracy of exosome functional research.

Method used

Functional exosomes are constructed using Gateway cloning technology, and the expression vector is generated through recombination of entry-level vectors and receiving vectors, introduced into host cells, and the specific membrane proteins and functional genes are fused to form marker or guided exosomes, achieving high-throughput rapid Clone and filter.

Benefits of technology

It realizes efficient marking and functional enhancement of exosomes, simplifies the insertion process of multiple functional genes or markers, improves the efficiency and accuracy of exosomes' functional research, and can be used for signal transmission, substance delivery, and in vivo tracer. Multiple functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061035A_ABST
    Figure CN119061035A_ABST
Patent Text Reader

Abstract

The invention discloses a method for constructing a functional exosome. The method comprises the following steps: constructing an entry vector by using a target gene; constructing an accepting vector by using the gene for coding the exosome specific membrane protein; triggering recombination of the entry vector and the accepting vector to generate an expression vector; introducing the expression vector into a host cell capable of secreting the exosome to obtain a functional exosome; the target gene comprises but is not limited to full-length or partial sequences of the following genes: an antibody, a cell factor, a protein tag, a fluorescent protein gene and a luciferase gene; the expression vector contains a fusion gene of the target gene and a gene for coding the exosome specific membrane protein. According to the invention, a high-throughput rapid cloning system marked by the exosome is formed, and various different functional genes or Tags are simply, conveniently and rapidly inserted into specific membrane proteins on the exosome, so that the exosome is marked, guided or functionally enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to a method for constructing functional exosomes. Background Art

[0002] Exosomes are extracellular vesicles with a size of about 30-150nm and a lipid bilayer membrane structure. They carry a large amount of important information such as proteins, lipids, DNA and RNA (miRNA, mRNA, lncRNA, circRNA), and not only participate in intercellular communication and information exchange, but also play an important role in antigen presentation, tumor growth and migration, tissue damage repair, etc., depending on the cell type from which the exosomes come.

[0003] Almost all cells in the human body can secrete exosomes under normal or pathological conditions, such as immune cells, endothelial cells, tumor cells, etc. Exosomes from different cell sources also have certain differences in the functional characteristics of the active substances they contain. When exosomes are secreted by host cells and delivered to receptor cells, they mainly regulate or change the functions and physiological states of receptor cells through the active substances they contain. Research in recent years has confirmed that the contents of exosomes (such as miRNA) are closely related to diseases, such as participating in immune diseases, viral infections, the spread of neurodegenerative diseases, cancer occurrence and metastasis, etc., and can be used as biomarkers for disease diagnosis.

[0004] It has been reported that transmembrane proteins such as CD63, CD9, CD81, and FPRP are specifically expressed and enriched on the membrane of exosomes. Research on the functionality of exosomes has been carried out in various fields in recent years. Summary of the invention

[0005] The purpose of the present application is to at least overcome the deficiencies of the prior art and provide a rapid method for constructing functional exosomes suitable for high-throughput operations.

[0006] In order to achieve the above technical objectives, the technical solutions adopted in this application are as follows:

[0007] A method for constructing functional exosomes, comprising the following steps:

[0008] Construct an entry vector using the target gene;

[0009] The receiving vector is constructed using genes encoding exosome-specific membrane proteins;

[0010] Triggering the entry vector to recombine with the receiving vector to generate an expression vector;

[0011] Introducing the expression vector into a host cell that can secrete exosomes to obtain functional exosomes;

[0012] The target gene includes but is not limited to the full-length or partial sequence of the following genes: antibodies, cytokines, protein tags, fluorescent protein genes, luciferase genes;

[0013] The expression vector contains a fusion gene of the target gene and a gene encoding an exosome-specific membrane protein.

[0014] Optionally, the receiving vector is a lentiviral vector.

[0015] Preferably, the lentiviral vector inserts an attR1 element upstream of the CmR gene and an attR2 element downstream of the ccdb gene, respectively, and then is connected to the gene encoding the exosome-specific membrane protein to form the receiving vector; the attB1 element and the attB2 element are connected to both ends of the target gene, respectively, to construct an entry vector.

[0016] Alternatively, the lentiviral vector is introduced into the gene encoding the exosome-specific membrane protein by PCR amplification.

[0017] Furthermore, the gene encoding the exosome-specific membrane protein is pre-constructed into a transfer vector.

[0018] Preferably, PCR is used to screen the recipient vector and / or expression vector.

[0019] Optionally, the protein tag includes but is not limited to the following types: Snap / Clip Tag, HaloTag, AviTag; the fluorescent protein gene includes but is not limited to the following types: GFP, RFP, mCherry; the luciferase gene includes but is not limited to the following types: GLuc, FLuc, RLuc, nanoLuc.

[0020] Further optionally, the gene encoding the exosome-specific membrane protein includes but is not limited to the full-length or partial sequence of the following genes: CD63, CD9, CD81 or FPRP.

[0021] In some embodiments, when the receiving vector is constructed using the full-length or partial sequence of CD63, the primer pairs used are the nucleic acid sequence shown in SEQ ID No.1 and the nucleic acid sequence shown in SEQ ID No.2; when the receiving vector is constructed using the full-length or partial sequence of FPRP, the primer pairs used are the nucleic acid sequence shown in SEQ ID No.3 and the nucleic acid sequence shown in SEQ ID No.4.

[0022] Compared with the prior art, this application has the following advantages:

[0023] The present application provides a method for constructing functional exosomes, forming a high-throughput rapid cloning system for exosome labeling; this cloning system uses Gateway technology to simply and quickly insert a variety of different functional genes or tags into specific membrane proteins on exosomes, so that the exosomes are labeled, guided or functionally enhanced. First, on the cloning vectors of specific membrane proteins on exosomes, such as CD63, CD9, CD81, FPRP, etc., according to the characteristics of different membrane proteins, the Gateway cloning sequence attR element is introduced into a specific position. Then, these cloning vectors are used as receiving vectors (Destination Vector), and various gene markers or functional or directional tags to be tested are selected from the gene library of EntryClones, and introduced into these exosome-specific membrane proteins through LR reaction to generate fusion genes. The present application can not only efficiently label exosomes, but also can high-throughput screen the influence and effect of the expression of various genes on the exosome membrane on the function of exosomes, including exosome guidance and functional gain. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a schematic diagram of the cell membrane structure of the functional exosomes that can be formed in the present application, showing the different functional tags and gene markers of the exosomes.

[0025] Figure 2 The key sequence diagram of the CD63-containing acceptor vector constructed using the method of the present application.

[0026] Figure 3 This is a key sequence diagram of the acceptor vector containing FPRP constructed using the method of the present application. DETAILED DESCRIPTION

[0027] The present application is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.

[0028] This application mainly cites the Gateway cloning technology to complete the functional modification of exosomes. Gateway cloning technology is an efficient large-scale cloning system that utilizes the site-specific recombination of human bacteriophages (human phages use this recombination system to convert between the lytic pathway and the lysogenic pathway), achieving rapid gene cloning and parallel transfer between vectors without the need for traditional enzyme cutting and ligation processes, while maintaining the correct reading frame and direction. The Gateway cloning method is an in vitro form of the integration and cutting recombination reaction that occurs when lambda phage infects bacteria. In vivo, the attachment site of the phage (attP element) and the attachment site of the bacteria (attB element) undergo a recombination reaction, and the phage is integrated into the bacterial genome, flanked by two new recombination sites (attL element and attR element). Under certain conditions, the attL and attR sites can recombine, causing the phage to be excised from the bacterial chromosome and regenerate the attP and attB sites.

[0029] The basic process of Gateway cloning is as follows:

[0030] (1) BP reaction: The target gene is connected to the donor vector to form an entry clone (also called an entry vector). The attB sites are added to both sides of the target DNA sequence through PCR to form attB-PCR products. The attB-PCR product or the donor plasmid containing attB sites (Donor Vector) and the plasmid containing attP sites are used to recombine to generate the entry clone (Entry Clone).

[0031] (2) LR reaction: The entry clone with attL site undergoes LR reaction with the receiving vector with attR site, and the target gene is recombined from the entry clone to the destination vector to form an expression clone (Expression Clone, also called expression vector). After completing the BP reaction and LR reaction, the next step is transformation and positive clone screening, which is the same as other vector construction methods. The entry clone and the destination vector carry different antibiotic markers, and the expression clone can be selected by using antibiotics. When performing the recombination reaction, it is necessary to use an E. coli strain that is sensitive to CcdB, such as DH5α, TOP10, and Mach1-T1.

[0032] By the method of the present application, functional exosomes with luciferase protein, fluorescent protein, protein tag, cytokine or functional antibody can be constructed, specifically, the aforementioned protein is combined with the transmembrane protein of the exosome to form a fusion protein, such as Figure 1 As shown in the schematic diagram.

[0033] The implementation steps of this application are as follows:

[0034] (1) Construction of entry vector

[0035] A gene that can confer certain functionality to exosomes is selected as the target gene, and attB1 and attB2 elements are added to both ends of the target gene to allow a BP reaction to occur with the receptor plasmid. The target gene is connected to the receptor plasmid to form an entry vector, wherein the receptor plasmid contains attP1 and attP2 elements before the BP reaction. In the BP reaction principle, the attB1 element only reacts with the attP1 element, and the attB2 element only reacts with the attP2 element. After the BP reaction, attL1 and attL2 elements are formed on the receptor plasmid. Functionally, the receptor plasmid becomes an entry vector for participating in the subsequent LP reaction.

[0036] The target genes selected in this application include but are not limited to the full-length or partial sequences of the following genes: antibodies, cytokines, protein tags, fluorescent protein genes, and luciferase genes. Antibodies and cytokines can be used to functionally modify exosomes, giving exosomes additional messenger functions, or being able to strengthen or weaken the original messenger functions. Protein tags can be used to study protein-protein interactions or protein-nucleic acid interactions, making exosomes a research tool. Fluorescent proteins and luciferases make exosomes more obviously traceable and labeling. More specifically, the protein tags include but are not limited to the following types: Snap / Clip Tag, HaloTag, AviTag; the fluorescent protein genes include but are not limited to the following types: GFP, RFP, mCherry; the luciferase genes include but are not limited to the following types: GLuc, FLuc, RLuc, nanoLuc.

[0037] Construction of receiving vector

[0038] The receiving vector of the present application contains a gene encoding an exosome-specific membrane protein, and the gene encoding an exosome-specific membrane protein is selected from one of the following according to current research progress: CD63, CD9, CD81 or FPRP. The receiving vector of the present application contains attR1 elements and attR2 elements before the LP reaction, which are used to react with attL1 elements and attL2 elements to facilitate the insertion of the gene sequence between attL1 elements and attL2 elements into the receiving vector to form an expression vector. In the aforementioned steps, the target gene is inserted between the attL1 element and the attL2 element. Specifically, one of the construction methods of the vector (plasmid) participating in the LR reaction is as follows:

[0039] Construction method of LR plasmid

[0040] 1. Experimental Materials

[0041] Reagents: DNA Polymerase (Gencopoeia, C0103A); Primer Oligo (Invitrogen); Cloning vector CS-Flag-nLuc-FPRP-mCherry-01-Lv195 (Genecopoeia); Cloning vector CS-CoV219-Lv195-01 (Genecopoeia); Cloning vector pEZ-Lv203 (Genecopoeia) Fast-Fusion TM Cloning Kit (Gencopoeia, FFPC-C020); Gel Recovery Kit (Omega); 2T1 competent cells (Genecopoeia, U0104A); STBL3 competent cells (Genecopoeia, U0103A); Restriction endonucleases (Fermentas); DNA Ladder (Genecopoeia); Gel Extraction Kit(OMEGA);UltraPF TM DNA Polymerase Kit (Genecopoeia, C0103A); Plasmid Mini KitⅠ(OMEGA); Endotoxin-free plasmid mini / mid extraction kit (Omega).

[0042] 2. Experimental Procedure

[0043] In this example, the exosome marker cloning vector is inserted into a lentiviral vector, and the specific steps are as follows:

[0044] A. Vector Design

[0045] The present application constructs two different gene-receiving vectors encoding exosome-specific proteins. The attR1-CmR-ccdb-attR2 sequence is inserted into the specific position of the exosome membrane protein CD63 and FPRP in the vector to construct a receiving vector. The key sequences are as follows: Figure 2 and Figure 3 As shown in the figure, various gene markers, functional or directional tags to be tested can be fused to the exosome membrane proteins CD63 and FPRP at high throughput and speed.

[0046] LR vector construction:

[0047] attR1-CmR-ccdb-attR2 was cloned into CS-CD63-Lv195 to obtain CS-CD63-Lv195_attR;

[0048] attR1-CmR-ccdb-attR2 was cloned into CS-FPRP-Lv195 to obtain CS-FPRP-Lv195-attR.

[0049] Build steps:

[0050] (1) Acquisition of fragment M that can be inserted into attR1-CmR-ccdb-attR2

[0051] The primers listed in Table 1 were designed and synthesized according to the inserted sequences.

[0052] Primer name sequence CD63-ccdb-PF gattgccgtgggtgtcggggcacagACAAGTTTGTACAAAAAAGCTG CD63-ccdb-PR attatggtctgactcaggacaaggACCACTTTGTACAAGAAAGCTG FPRP-ccdb-PF ttgccgagggcgtgtggtgagaACAAGTTTGTACAAAAAAGCTG FPRP-ccdb-PR ccgcctcccgagccgcctcctccgACCACTTTGTACAAGAAAGCTG

[0053] Dilute the primers in Table 1 to 10 pmol / μL for later use;

[0054] The inserted sequence was amplified by synthetic PCR: using CD63-ccdb-PF / CD63-ccdb-PR in Table 1 as primers and pEZ-Lv203 as template, the fragment attR1-CmR-ccdb-attR2 (CD63) was amplified, and the PCR reaction system was shown in Table 2; using FPRP-ccdb-PF / FPRP-ccdb-PR in Table 1 as primers and pEZ-Lv203 as template, the fragment attR1-CmR-ccdb-attR2 (FPRP) was amplified, and the PCR reaction system was shown in Table 2.

[0055] Table 2. PCR reaction system

[0056] Reagent name 1× Volume <![CDATA[5×UltraPF TM Buffer]]> 5μL dNTPs (25 mM) 0.2μL <![CDATA[Mg 2+ (50mM)]]> 0.75μL <![CDATA[UltraPF TM DNA Polymerase(5U / μL)]]> 0.2μL CD63-ccdb-PF 1μL CD63-ccdb-PR 1μL pEZ-Lv203 1μL <![CDATA[ddH2O]]> Add to 25 μL

[0057]

[0058] Table 3. PCR reaction program

[0059]

[0060] B. Clone the synthetic insert fragment M into the destination vector

[0061] 2.1. Enzyme digestion of vector

[0062] According to Table 4, the enzyme digestion system was established using OMEGA The vector digestion product was recovered by Gel Extraction Kit and cloned into vectors CS-CD63-Lv195 (Genecopoeia); CS-FPRP-Lv195 (Genecopoeia).

[0063] Table 4 Enzyme digestion system

[0064] Reagents Dosage CS-CD63-Lv195 3μg 10×NEB buffer 4μL BamHI(NEB) 0.8μL (10μ / μL) <![CDATA[ddH2O]]> Add to 40 μL

[0065]

[0066]

[0067] 2.2. Ligation of synthetic insert fragment M and plasmid vector

[0068] In-fusion reaction was performed using Fast-Fusion Cloning Kit. After the reaction, 5 μL was taken to transform E. coli competent cells DB31 and resistance screening was performed using A+C.

[0069] 2.3. PCR screening of gene recombinant clones

[0070] Each PCR reaction system was divided into 16 μL ddH2O and 1 μL vector primer (primer sequence: GGGTGGAGACTGAAGTTAGGCCAG and CACCCTAACTGACACACATTCCAC) (5 pmol / μL). The PCR reaction procedure is as shown in Table 5. The PCR product was detected by electrophoresis, the size of the DNA fragment was estimated by comparing with the marker, and the positive clone containing the target DNA fragment was selected. Plasmid DNA was extracted using Plasmid Mini KitI, the plasmid was sent for sequencing, and the correct LR clone was selected.

[0071] Table 5. PCR reaction program

[0072]

[0073] Finally, attR1-CmR-ccdb-attR2 was cloned into CS-CD63-Lv195 to obtain CS-CD63-Lv195_attR; attR1-CmR-ccdb-attR2 was cloned into CS-FPRP-Lv195 to obtain CS-FPRP-Lv195-attR.

[0074] (3) Construction of expression vector

[0075] In the LR reaction principle, the attL1 element only reacts with the attR1 element, and the attL2 element only reacts with the attR2 element. After the LR reaction, the attB1 element and attB2 element are formed on the receiving plasmid, and the receiving plasmid functionally becomes an expression vector for transformation and expression.

[0076] Example 2: Construction method of recombinant plasmid

[0077] 1. Purpose: To transfer the cloned gene to the expression vector through LR reaction.

[0078] 2. Materials and Instruments:

[0079] 2.1. Consumables: 10μL, 200μL, 1000μL Tip; 0.5mL centrifuge tube.

[0080] 2.2. Reagents: plasmid of Entry clone (CS-Flag-Gluc dev & CS-HaloTag dev) (Genecopoeia), 5×BP Buffer (Genecopoeia), 5×LRase (Genecopoeia), ddH2O.

[0081] 2.3. Instruments: P-2 pipette, P-20 pipette, P-200 pipette, P-1000 pipette, desktop centrifuge, oscillator.

[0082] 3. Shuttle cloning (LR reaction) into the target vector

[0083] Table 6 LR reaction system

[0084] Reagents Dosage CS-Flag-Gluc dev 100-300ng CS-CD63-Lv195_attR 100ng 5×BP Buffer 2μL 5×LRase 2μL ddH2O Add to 10 μL

[0085] Reagents Dosage CS-Flag-nLuc-dev 100-300ng CS-FPRP-Lv195-attR 100ng 5×BP Buffer 2μL 5×LRase 2μL ddH2O Add to 10 μL

[0086] Incubate at 25°C for 60 minutes.

[0087] 4. Conversion

[0088] 4.1. Thaw the competent cells in ice.

[0089] 4.2. Use a pipette to transfer 4 μL of the reaction product into a sterile 1.5 mL EP tube, add 50-100 μL of competent cells, and place on ice for 30 minutes.

[0090] 4.3. Heat shock at 2℃ for 45 seconds, then place on ice for 2-3 minutes.

[0091] 4.4. Add 500 μL SOC medium and culture at 37°C with shaking (200 or 220 rpm) for 1 hour.

[0092] 4.5. Take 50 μL and 200 μL of culture and apply them to the TM vector(or pDESTvector) were used to generate agarose plates.

[0093] 4.6. Incubate at 7°C for 12-16 hours.

[0094] 5. PCR screening of gene recombination clones

[0095] Each PCR reaction system was divided into 16 μL ddH2O and 1 μL vector primer (primer sequence: GGGTGGAGACTGAAGTTAGGCCAG and CACCCTAACTGACACACATTCCAC) (5 pmol / μL). The PCR reaction procedure was as shown in Table 7. The PCR product was detected by electrophoresis, the size of the DNA fragment was estimated by comparing with the marker, and the positive clone containing the target DNA fragment was selected. Plasmid DNA was extracted using Plasmid Mini KitI, and the plasmid was sent for sequencing to select the correct recombinant clone.

[0096] Table 7. PCR reaction program

[0097]

[0098] Thus, an expression vector for inserting multiple genes or tags with different functions into specific membrane proteins on exosomes is obtained.

[0099] (4) The expression vector is expressed in host cells, and the host cells produce fusion proteins encoded by the expression vector. These fusion proteins are concentrated in exosomes, thereby obtaining functional exosomes.

[0100] In summary, the method for constructing functional exosomes provided in the present application forms a high-throughput rapid cloning system for exosome labeling, which can easily and quickly insert a variety of different functional genes or tags into specific membrane proteins on exosomes, so that the exosomes are labeled, guided or functionally enhanced, so that the functional exosomes can achieve multiple functions such as signal transmission, substance delivery, and in vivo tracing.

[0101] The above embodiments are preferred implementation modes of the present application, but are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present application should be equivalent replacement methods and are included in the protection scope of the present application.

Claims

1. A method for constructing functional exosomes, characterized in that: It includes the following steps: Construct an entry vector using the target gene; The receiving vector is constructed using genes encoding exosome-specific membrane proteins; Triggering the entry vector to recombine with the receiving vector to generate an expression vector; Introducing the expression vector into a host cell that can secrete exosomes to obtain functional exosomes; The target gene includes but is not limited to the full-length or partial sequence of the following genes: antibodies, cytokines, protein tags, fluorescent protein genes, luciferase genes; The expression vector contains a fusion gene of the target gene and a gene encoding an exosome-specific membrane protein.

2. The method according to claim 1, characterized in that The receiving vector is a lentiviral vector.

3. The method according to claim 2, characterized in that The lentiviral vector inserts the attR1 element upstream of the CmR gene and the attR2 element downstream of the ccdb gene, and then connects with the gene encoding the exosome-specific membrane protein to form the receiving vector; the two ends of the target gene are connected to the attB1 element and the attB2 element, respectively, to construct an entry vector.

4. The method according to claim 3, characterized in that The lentiviral vector is introduced into the gene encoding the exosome-specific membrane protein by PCR amplification.

5. The method according to claim 4, characterized in that The gene encoding the exosome-specific membrane protein is pre-constructed into a transfer vector.

6. The method according to claim 1, characterized in that The receiving vector and / or expression vector is screened by PCR.

7. The method according to claim 1, characterized in that The protein tags include but are not limited to the following types: Snap / Clip Tag, HaloTag, AviTag; the fluorescent protein genes include but are not limited to the following types: GFP, RFP, mCherry; the luciferase genes include but are not limited to the following types: GLuc, FLuc, RLuc, nanoLuc.

8. The method according to claim 1, characterized in that The gene encoding the exosome-specific membrane protein includes but is not limited to the full-length or partial sequence of the following genes: CD63, CD9, CD81 or FPRP.

9. The method according to claim 8, characterized in that When the receiving vector is constructed using the full-length or partial sequence of CD63, the primer pairs used are the nucleic acid sequence shown in SEQ ID No.1 and the nucleic acid sequence shown in SEQ ID No.2; when the receiving vector is constructed using the full-length or partial sequence of FPRP, the primer pairs used are the nucleic acid sequence shown in SEQ ID No.3 and the nucleic acid sequence shown in SEQ ID No.4.